A new SARS-CoV-2 variant has one or more mutations that differentiate it from predominant virus variants already circulating among the general population. Variants are expected to occur as viruses are constantly changing. Surveillance can help investigate how some variants may impact COVID-19 disease transmission or severity and the effectiveness of vaccines and therapeutics.
Table 1 Critical emerging mutants
ACROBiosystems are going full steam ahead on developing a collection of recombinant antigens for these variants, including Spike proteins and Nucleocapsid proteins, covering critical mutations such as K417N/T, E484K, N501Y and D614G on Spike protein and R203G, G204R and P13L on Nucleocapsid protein. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
All critical mutations covered
• Full length S trimer with multiple mutations
• 6P and 2A mutations make the protein more stable
• Suitable for antibody derection
Broad-spectrum neutralizing antibody
It is exciting that an anti-SARS-CoV-2 Spike RBD neutralizing antibody (Cat. No. S1N-M122) developed by ACROBiosystems retains potent neutralizing activity against popular SARS-CoV-2 variants as tested by pseudovirus assay. The broad-spectrum neutralizing antibody is suitable to be a positive control in neutralization antibody screening, QC test reagent for both recombinant protein vaccines and COVID-19 neutralizing antibody detection in vaccinated serum.
High Purity verified by MALS
The purity of SARS-CoV-2 S protein, His Tag(Cat. No. SPN-C52H6) was more than 90% and the molecular weight of this protein is around 520-560 kDa verified by SEC-MALS.
Binding to ACE2 and neutralizing antibody well
Immobilized SARS-CoV-2 S1 protein (D614G), His Tag (Cat. No. S1N-C5256) at 2 μg/mL (100 μL/well) can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.2-3 ng/mL.
Immobilized SARS-CoV-2 S1 protein (D614G), His Tag (Cat. No. S1N-C5256) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) with a linear range of 0.2-3 ng/mL.